Effect of montelukast compared with inhaled fluticasone on airway inflammation

Clinical and Experimental Allergy

Volumn 34, Issue 9, 2004, Pages 1388-1394

  Overbeek, S E ^a   O'Sullivan, S ^b   Leman, K ^a   Mulder, P G H ^a   Hoogsteden, H C ^a   Prins, J B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Airway inflammation; Asthma; Fluticasone propionate; Montelukast

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE; LEUKOTRIENE E4; MONTELUKAST; PROSTAGLANDIN F2;

ADULT; ALLERGIC ASTHMA; ARTICLE; BRONCHUS BIOPSY; CELL ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME IMMUNOASSAY; EOSINOPHIL; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LAMINA PROPRIA; MAST CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ACETATES; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DOUBLE-BLIND METHOD; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-5; LEUKOTRIENE ANTAGONISTS; LUNG; MALE; MAST CELLS; MIDDLE AGED; QUINOLINES; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 4544303453     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02041.x     Document Type: Article

References (31)

1. Busse WW. Inflammation in asthma: the cornerstone of the disease and target of therapy. J Allergy Clin Immunol 1998; 102:S17-22.
2. Global Strategy for asthma management and prevention. National Heart, Lung and Blood Institute report. National Institutes of Health. Revised 2002.
3. Burke CM, Sreenan S, Pathmakanthan S, Patterson J, Schmekel B, Poulter LW. Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma: a controlled study. Thorax 1996; 51:993-9.
4. Barnes NC, Burke CM, Poulter LW, Schleimer RP. The anti-inflammatory profile of inhaled corticosteroids: biopsy studies in asthmatic patients. Respir Med 2000; 94:S16-21.
5. Barnes NC. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 2000; 161:573-6.
6. Yoshida A, Ishizaki, Shoji T et al. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000; 30:1008-14.
7. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12-8.
8. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Bronchoalveolar lavage fluid findings after segmental allergen challenge. Am J Respir Crit Care Med 1998; 157:1381-9.
9. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53:835-41.
10. Malmstrom K., Rodriguez-Gomez G, Guerra J et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487-95.
11. Busse W, Raphael GD, Galant S et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107:461-8.
12. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002; 109:68-74.
13. Bleecker ER, Welch MJ, Weinstein SF, Johnson C, Edwards L, Rickard KA. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105:1123-9.
14. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349-52.
15. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149:953-9.
16. Drazen JM. Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 1998; 158 (5 Part 3):S193-200.
17. Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7:235-43.
18. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of a high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 151:45-52.
19. Djukanovic R, Wilson JW, Britten KM et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-74.
20. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast verus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002; 20:853-8.
21. O'Sullivan S, Akevld M, Burke CM, Poulter LW. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation. Am J Respir Crit Care Med 2003; 167:745-50.
22. Djukanovic R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142:434-57.
23. O'Sullivan S, Cormican L, Murphy M, Poulter LW, Burke CM. Effect of varying doses of inhaled corticosteroids on the physiology and bronchial wall immunopathology in mild to moderate asthma. Chest 2002; 122:1966-72.
24. Minoguchi K, Kohno Y, Minoguchi H et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121:732-8.
25. Diamant Z, Grootendorst DC, Veselic-Charvat M et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999; 29:42-51.
26. Grootendorst DC, Sont JK, Willems LN et al. Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy 1997; 27:769-79.
27. Bleeker ER, Welch MJ, Weinstein SF et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105:1123-9.
28. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003; 167:1232-8.
29. Cockcroft DW. How best to measure airway responsiveness. Am J Respir Crit Care Med 2001; 163:1514-5.
30. Chu HW, Halliday JL, Martin RJ et al. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998; 158:1936-44.
31. Ward C, Pais M, Bish R et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57:309-16.